These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

165 related articles for article (PubMed ID: 21511951)

  • 1. Preclinical pharmacological profile of the selective 5-HT1F receptor agonist lasmiditan. A comment.
    Maggioni F; Pini LA; Zanchin G
    Cephalalgia; 2011 Jul; 31(9):1061. PubMed ID: 21511951
    [No Abstract]   [Full Text] [Related]  

  • 2. Targeting to 5-HT1F receptor subtype for migraine treatment: lessons from the past, implications for the future.
    Mitsikostas DD; Tfelt-Hansen P
    Cent Nerv Syst Agents Med Chem; 2012 Dec; 12(4):241-9. PubMed ID: 22934751
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Acute treatment of migraine with the selective 5-HT1F receptor agonist lasmiditan--a randomised proof-of-concept trial.
    Ferrari MD; Färkkilä M; Reuter U; Pilgrim A; Davis C; Krauss M; Diener HC;
    Cephalalgia; 2010 Oct; 30(10):1170-8. PubMed ID: 20855362
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Preclinical pharmacological profile of the selective 5-HT1F receptor agonist lasmiditan.
    Nelson DL; Phebus LA; Johnson KW; Wainscott DB; Cohen ML; Calligaro DO; Xu YC
    Cephalalgia; 2010 Oct; 30(10):1159-69. PubMed ID: 20855361
    [TBL] [Abstract][Full Text] [Related]  

  • 5. 5-Hydroxyptryptamine 1F (5-HT1F) receptor agonism. A possible new treatment principle for acute migraine attacks.
    Olesen J
    Cephalalgia; 2010 Oct; 30(10):1157-8. PubMed ID: 20855360
    [No Abstract]   [Full Text] [Related]  

  • 6. Molecule of the month. Lasmiditan hydrochloride.
    Drug News Perspect; 2010 Sep; 23(7):455. PubMed ID: 20862397
    [No Abstract]   [Full Text] [Related]  

  • 7. Treatment of acute migraine.
    Miller FG
    Lancet; 2002 Mar; 359(9308):802. PubMed ID: 11888631
    [No Abstract]   [Full Text] [Related]  

  • 8. Lasmiditan mechanism of action - review of a selective 5-HT
    Clemow DB; Johnson KW; Hochstetler HM; Ossipov MH; Hake AM; Blumenfeld AM
    J Headache Pain; 2020 Jun; 21(1):71. PubMed ID: 32522164
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Lasmiditan for the treatment of migraine.
    Capi M; de Andrés F; Lionetto L; Gentile G; Cipolla F; Negro A; Borro M; Martelletti P; Curto M
    Expert Opin Investig Drugs; 2017 Feb; 26(2):227-234. PubMed ID: 28076702
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Serotonin receptor targeted therapy for migraine treatment: an overview of drugs in phase I and II clinical development.
    Barbanti P; Aurilia C; Egeo G; Fofi L; Palmirotta R
    Expert Opin Investig Drugs; 2017 Mar; 26(3):269-277. PubMed ID: 28103158
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The safety and efficacy of the 5-HT 1F receptor agonist lasmiditan in the acute treatment of migraine.
    Raffaelli B; Israel H; Neeb L; Reuter U
    Expert Opin Pharmacother; 2017 Sep; 18(13):1409-1415. PubMed ID: 28749698
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Short-term efficacy and safety of lasmiditan, a novel 5-HT
    Hou M; Xing H; Li C; Wang X; Deng D; Li J; Zhang P; Chen J
    J Headache Pain; 2020 Jun; 21(1):66. PubMed ID: 32503415
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Profiling lasmiditan as a treatment option for migraine.
    Curto M; Cipolla F; Cisale GY; Capi M; Spuntarelli V; Guglielmetti M; Martelletti P; Lionetto L
    Expert Opin Pharmacother; 2020 Feb; 21(2):147-153. PubMed ID: 31766908
    [No Abstract]   [Full Text] [Related]  

  • 14. The Effect and Safety of 5-HT
    Gu P; Chen C; Wu Q; Dong C; Wang T; Wan Q; Dong X
    Biomed Res Int; 2021; 2021():6663591. PubMed ID: 34660796
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Possible antimigraine mechanisms of action of the 5HT1F receptor agonist LY334370.
    Shepheard S; Edvinsson L; Cumberbatch M; Williamson D; Mason G; Webb J; Boyce S; Hill R; Hargreaves R
    Cephalalgia; 1999 Dec; 19(10):851-8. PubMed ID: 10668103
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Targeted 5-HT
    Vila-Pueyo M
    Neurotherapeutics; 2018 Apr; 15(2):291-303. PubMed ID: 29488143
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Drugs targeting 5-hydroxytryptamine receptors in acute treatments of migraine attacks. A review of new drugs and new administration forms of established drugs.
    Tfelt-Hansen PC; Pihl T; Hougaard A; Mitsikostas DD
    Expert Opin Investig Drugs; 2014 Mar; 23(3):375-85. PubMed ID: 24289494
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Lasmiditan: First Approval.
    Lamb YN
    Drugs; 2019 Dec; 79(18):1989-1996. PubMed ID: 31749059
    [TBL] [Abstract][Full Text] [Related]  

  • 19. 5-HT1F receptor agonists inhibit neurogenic dural inflammation in guinea pigs.
    Johnson KW; Schaus JM; Durkin MM; Audia JE; Kaldor SW; Flaugh ME; Adham N; Zgombick JM; Cohen ML; Branchek TA; Phebus LA
    Neuroreport; 1997 Jul; 8(9-10):2237-40. PubMed ID: 9243618
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The 5-HT1F receptor agonist lasmiditan as a potential treatment of migraine attacks: a review of two placebo-controlled phase II trials.
    Tfelt-Hansen PC; Olesen J
    J Headache Pain; 2012 Jun; 13(4):271-5. PubMed ID: 22430431
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.